Lv75
3406 积分 2025-05-12 加入
Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
2个月前
已完结
A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson’s disease
6个月前
已完结
B3Pdb: an archive of blood–brain barrier-penetrating peptides
6个月前
已完结
Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome
6个月前
已完结
Phase Ib Study Design Evaluating The Safety, Pharmacokinetics And Pharmacodynamics Of Selnoflast, A Novel NLRP3 Inflammasome Inhibitor In Early-Stage PD (P2-11.007)
6个月前
已关闭
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
6个月前
已完结
Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor
6个月前
已完结
A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis
6个月前
已完结
Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
6个月前
已关闭
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
6个月前
已完结
皖公网安备34019202002308
